Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104923 · ClinicalTrials.gov registry record · Phase 1
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by California Cancer Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 4
- Study locations
NCT00104923 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by California Cancer Consortium. The registered enrollment target is 29 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00104923, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by California Cancer Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving fenretinide in a different way may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating patients with refractory or relapsed hematologic cancer.
Conditions Studied
Interventions
- DRUG fenretinide
Study Locations (4)
Texas
- M. D. Anderson Cancer Center at University of Texas - Houston
- Joe Arrington Cancer Research and Treatment Center - Lubbock
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-02 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104923
The ClinicalTrials.gov registry entry for NCT00104923 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The listed sponsor is California Cancer Consortium, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which fenretinide is the first listed.
NCT00104923 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT00104923 about?
NCT00104923 is a clinical study titled "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer". RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving fenretinide in a different way may kill more cancer cells. PURPOSE: This phase I trial is studying the side ef...
What is the current status of trial NCT00104923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2005-02. Estimated completion is 2017-04.
What conditions does trial NCT00104923 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Chronic Myeloproliferative Disorders.
What interventions are being tested in trial NCT00104923?
The interventions under investigation include: fenretinide (DRUG).
Who is sponsoring clinical trial NCT00104923?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104923 being conducted?
This trial has 4 study locations across California, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.